Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price3,209.20 INR
Ethical score0.0/100
RatingAVOID
Our investment reviews on this name
2026-10-02Read Markdown3,209.20+0.0% to today
2026-09-05Read Accumulation3,050.10+5.2% to today ✓
2026-07-30Read Markup3,050.10+5.2% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Grasim Industries holds its Markdown at $3,209.20. The statistical read favours the buyers, held for 20 days.
As held on the ledger · 2026-09-18
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 20 days
Price at the screen
$3,209.20
Valuation
0.00 trailing · 0.00 forward price to earnings
Values screen
FAIL· score 0.0
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
40.00%
Below 33%
Interest-bearing debt is 40.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
14.19%
Below 33%
Cash held in interest-bearing accounts and securities is 14.2% of assets, under the one-third limit.
Pass
Receivables
2.41%
Below 49%
Money owed to the company is 2.4% of assets, under the 49% limit.
Pass
Revenue purity
0.22%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Grasim Industries's business is in a permissible area, but its interest-bearing debt is about 40% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
On our numbers, the price already runs ahead of the business.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GRASIM.NS trades on NSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it strong buy, with a mean price target of $3476.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it strong buy, with a mean price target of $3476.
2026-08-06Markup$3,050.10+0.0%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it strong buy, with a mean price target of $3476. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-05Markup$3,050.10+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it strong buy, with a mean price target of $3476. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-04Markup$3,050.10+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it strong buy, with a mean price target of $3476. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-03Markup$3,050.10+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it strong buy, with a mean price target of $3476. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-02Markup$3,050.10+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it strong buy, with a mean price target of $3476. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-01Markup$3,050.10+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it strong buy, with a mean price target of $3476. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-31Markup$3,050.10+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it strong buy, with a mean price target of $3476. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-30Markup$3,050.10+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it strong buy, with a mean price target of $3476. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.